Christopher Viehbacher

Chief Executive Officer, Biogen

Appears in 1 story

Born: March 26, 1960, Kitchener

Education: Queen's University

Previous offices: chief executive officer

Last updated Nov 1, 2026

Stories

Eisai and Biogen launch Leqembi Iqlik autoinjector for at-home Alzheimer's treatment

New Capabilities

As of August 2026: Co-marketing Leqembi and IQLIK in the US

Since 2023 the Alzheimer's drug Leqembi came with a catch: patients needed intravenous infusions at a clinic every two weeks for 18 months. On August 24, Eisai and Biogen removed that hurdle, making a subcutaneous autoinjector version, LEQEMBI IQLIK, available from the very first dose.

Updated Aug 25